SCHEMBL15420893

SCHEMBL15420893

CCS(=O)(=O)N[C@H]1CCOC[C@@H]1COc1ccc(-c2cc(C)on2)c(F)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.33
RET P07949 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
FFAR1 O14842 1/20 0.31
HMOX1 P09601 1/20 0.31
FFAR4 Q5NUL3 2/20 0.31
CASP3 P42574 1/20 0.31
RAB9A P51151 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
PIK3R1 P27986 1/20 0.31
PIK3CA P42336 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
PPARG P37231 1/20 0.30
PPARA Q07869 1/20 0.30
AOC2 O75106 1/20 0.30
ADAM17 P78536 1/20 0.30
ALOX5AP P20292 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12987244 0.92 SCN9A (0.33) SCN9ARETMEN1KMT2AFFAR1
SCHEMBL15420622 0.91 RET (0.32) SCN9ARETFFAR1FFAR4CASP3
SCHEMBL15420153 0.90 SCN9A (0.33) SCN9ARETFFAR1FFAR4CASP3
SCHEMBL12986919 0.87 XDH (0.38) KMT2ARAB9AADAM17
SCHEMBL15441644 0.87 XDH (0.38) KMT2ARAB9AADAM17
SCHEMBL15420078 0.86 FFAR4 (0.37) RETMEN1KMT2AFFAR1FFAR4
SCHEMBL15420495 0.85 GRM5 (0.37) SCN9AFFAR1FFAR4PIK3R1PIK3CA
SCHEMBL12988572 0.85 GRM5 (0.37) SCN9AFFAR1FFAR4PIK3R1PIK3CA
SCHEMBL12988224 0.85 GRM5 (0.37) SCN9AFFAR1FFAR4PIK3R1PIK3CA
SCHEMBL15420177 0.85 SCN9A (0.32) SCN9AHMOX1FFAR4CASP3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 SCN9A 648/4885RET 533/4885MEN1 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.